Skip to main content
Pyxis Oncology, Inc. logo

Pyxis Oncology, Inc. — Investor Relations & Filings

Ticker · PYXS ISIN · US7473241013 US Manufacturing
Open in API
Filings indexed 308 across all filing types
Latest filing 2022-12-01 Regulatory Filings
Country US United States of America
Listing US PYXS

About Pyxis Oncology, Inc.

https://pyxisoncology.com/

Pyxis Oncology, Inc. is a clinical-stage company focused on developing next-generation therapeutics for difficult-to-treat cancers. The company's differentiated portfolio of clinical assets is centered on two primary modalities: antibody-drug conjugates (ADCs) and immuno-oncology (IO). Its ADC technology platform is designed to deliver potent cancer-killing agents directly to tumor cells for enhanced safety and efficacy. The immuno-oncology programs utilize monoclonal antibodies (mAbs) to mobilize the body's immune system to attack cancer cells by blocking tumor defense mechanisms and overcoming immune suppression. Pyxis Oncology is advancing its product candidates as both monotherapies and in combination with other therapies to improve outcomes for patients with solid tumors.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated December 1, 2022. It announces a press release about FDA clearance for two Investigational New Drug applications to initiate Phase 1 clinical trials. The document includes no financial statements or detailed financial data, only a brief event announcement and a press release attached as an exhibit. It is not an annual or quarterly report, nor an earnings release or management discussion. It is a regulatory filing reporting a material event. Therefore, it fits best under Regulatory Filings (RNS). The document length is 5483 characters, which is short and consistent with a Form 8-K event report rather than a full financial report.
2022-12-01 English
Regulatory Filings 2022
Regulatory Filings
2022-11-15 English
Regulatory Filings 2022
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC requesting acceleration of the effective date for a Registration Statement on Form S-3. It references a registration statement filing and is a formal communication related to the timing of a securities registration becoming effective. The document is short (1425 characters) and does not contain financial data or report content itself. It is an announcement/request related to a regulatory filing rather than the filing or report itself. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2022-11-10 English
Major Shareholding Notification 2022
Major Shareholding Notification
2022-11-04 English
Regulatory Filings 2022
Regulatory Filings
2022-11-03 English
S-3
Capital/Financing Update Classification · 100% confidence The document is a Form S-3 Registration Statement filed with the SEC by Pyxis Oncology, Inc. It is a registration statement under the Securities Act of 1933 for the offering and sale of securities including common stock, preferred stock, warrants, debt securities, rights, and units. The document includes a base prospectus and a sales agreement prospectus, describing the terms and conditions of securities offerings. It is not a financial report, earnings release, or management discussion, but a regulatory filing related to capital raising activities. The document is lengthy (15,000 characters) and contains detailed legal and offering information typical of a registration statement. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2022-11-01 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.